MONJUVI
Peaktafasitamab-cxix
BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
MONJUVI (tafasitamab-cxix) is tafasitamab-cxix is an fc-modified monoclonal antibody that binds to cd19 antigen expressed on the surface of pre-b and mature b lymphocytes and on several b-cell malignancies, including diffuse large b-cell lymphoma (dlbcl). First approved in 2020.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MONJUVI (tafasitamab-cxix) is an Fc-modified CD19-targeting monoclonal antibody approved for relapsed/refractory diffuse large B-cell lymphoma and other B-cell malignancies. It mediates B-cell lysis through apoptosis, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), with enhanced activity when combined with lenalidomide. The drug addresses a significant unmet need in heavily pretreated B-cell lymphoma patients who have exhausted standard therapies.
$1MPart D
PeakMONJUVI is in peak commercial phase with modest Part D spending, indicating a narrow patient population and specialized market requiring focused MSL and oncology-focused commercial teams.
Mechanism of Action
Tafasitamab-cxix is an Fc-modified monoclonal antibody that binds to CD19 antigen expressed on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL). Upon binding to CD19, tafasitamab-cxix mediates B-cell lysis through…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MONJUVI operates in the specialized hematologic oncology space requiring deep clinical expertise and strong relationships with academic medical centers and hematology-oncology specialists. Career opportunities favor MSLs, oncology brand managers, and medical science liaisons with expertise in monoclonal antibodies and combination immunotherapy strategies.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.